Indications for: SHINGRIX
Prevention of herpes zoster (shingles): in adults ≥50yrs of age; or in adults ≥18yrs of age at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy.
Limitations of Use:
Not for preventing primary varicella infection (chickenpox).
Give by IM inj in deltoid region of upper arm. ≥50yrs: one 0.5mL dose at Month 0 followed by second dose given between 2–6 months later. Immunocompromised (≥18yrs): one 0.5mL dose at Month 0 followed by second dose given between 1–2 months later.
<18yrs: not established.
Allergies to any previous Shingrix vaccination.
Review immunization history prior to administration. Have appropriate medical treatment and supervision available to manage allergic reactions. Syncope. Pregnancy. Nursing mothers.
Concomitant influenza vaccines: see full labeling.
Local reactions (eg, pain, redness, swelling), myalgia, fatigue, headache, shivering, fever, GI symptoms; Guillain-Barre syndrome, transient neurological effects.
To report adverse events, contact VAERS at (800) 822-7967.
Generic Drug Availability:
Single-dose vials—1, 10 (antigen + adjuvant components)